Patents by Inventor Johannes-Peter Stasch

Johannes-Peter Stasch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted 5-fluoro-1H-pyrazolopyridines and their use
    Patent number: 12064429
    Abstract: The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: August 18, 2022
    Date of Patent: August 20, 2024
    Assignee: Adverio Pharma GmbH
    Inventors: Markus Follmann, Johannes-Peter Stasch, Gorden Redlich, Jens Ackerstaff, Nils Griebenow, Walter Kroh, Andreas Knorr, Eva-Maria Becker, Frank Wunder, Volkhart Min-Jian Li, Elke Hartmann, Joachim Mittendorf, Karl-Heinz Schlemmer, Rolf Jautelat, Donald Bierer
  • SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE
    Publication number: 20220409618
    Abstract: The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: August 18, 2022
    Publication date: December 29, 2022
    Applicant: Adverio Pharma GmbH
    Inventors: Markus Follmann, Johannes-Peter Stasch, Gorden Redlich, Jens Ackerstaff, Nils Griebenow, Walter Kroh, Andreas Knorr, Eva-Maria Becker, Frank Wunder, Volkhart Min-Jian Li, Elke Hartmann, Joachim Mittendorf, Karl-Heinz Schlemmer, Rolf Jautelat, Donald Bierer
  • Substituted 5-fluoro-1H-pyrazolopyridines and their use
    Patent number: 11439642
    Abstract: The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: September 13, 2022
    Assignee: ADVERIO PHARMA GMBH
    Inventors: Markus Follmann, Johannes-Peter Stasch, Gorden Redlich, Jens Ackerstaff, Nils Griebenow, Walter Kroh, Andreas Knorr, Eva-Maria Becker, Frank Wunder, Volkhart Min-Jian Li, Elke Hartmann, Joachim Mittendorf, Karl-Heinz Schlemmer, Rolf Jautelat, Donald Bierer
  • Branched 3-phenylpropionic acid derivatives and their use
    Patent number: 11377417
    Abstract: The present application relates to novel 3-phenylpropionic acid derivatives which carry a branched or cyclic alkyl substituent in the 3-position, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: July 5, 2022
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Michael Hahn, Thomas Lampe, Johannes-Peter Stasch, Karl-Heinz Schlemmer, Frank Wunder, Volkhart Min-Jian Li, Eva Maria Becker-Pelster, Friederike Stoll, Andreas Knorr, Elisabeth Woltering
  • STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF
    Publication number: 20220023246
    Abstract: The present invention relates to stimulators and activators of soluble guanylate cyclase in combination with an inhibitor of neutral endopeptidase and/or angiotensin AII antagonists and the use thereof for the treatment and/or prophylaxis of cardiovascular disorders, for example heart failure with preserved ejection fraction or heart failure with reduced ejection fraction, renal disorders, for example chronic kidney failure, urological disorders, lung disorders, disorders of the central nervous system, for regulation of cerebral perfusion, for example in the event of vascular cerebral states of dementia, for the treatment and/or prophylaxis of fibrotic disorders and other disease symptoms (e.g. end organ damage affecting the brain, kidney or heart).
    Type: Application
    Filed: October 5, 2021
    Publication date: January 27, 2022
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Tobias MARQUARDT, Markus FOLLMANN, Johannes-Peter STASCH
  • Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof
    Patent number: 11166932
    Abstract: The present invention relates to stimulators and activators of soluble guanylate cyclase in combination with an inhibitor of neutral endopeptidase and/or angiotensin AII antagonists and the use thereof for the treatment and/or prophylaxis of cardiovascular disorders, for example heart failure with preserved ejection fraction or heart failure with reduced ejection fraction, renal disorders, for example chronic kidney failure, urological disorders, lung disorders, disorders of the central nervous system, for regulation of cerebral perfusion, for example in the event of vascular cerebral states of dementia, for the treatment and/or prophylaxis of fibrotic disorders and other disease symptoms (e.g. end organ damage affecting the brain, kidney or heart).
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: November 9, 2021
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Tobias Marquardt, Markus Follmann, Johannes-Peter Stasch
  • SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE
    Publication number: 20200397785
    Abstract: The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: July 2, 2020
    Publication date: December 24, 2020
    Applicant: Adverio Pharma GmbH
    Inventors: Markus Follmann, Johannes-Peter Stasch, Gorden Redlich, Jens Ackerstaff, Nils Griebenow, Walter Kroh, Andreas Knorr, Eva-Maria Becker, Frank Wunder, Volkhart Min-Jian Li, Elke Hartmann, Joachim Mittendorf, Karl-Heinz Schlemmer, Rolf Jautelat, Donald Bierer
  • BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE
    Publication number: 20200385335
    Abstract: The present application relates to novel 3-phenylpropionic acid derivatives which carry a branched or cyclic alkyl substituent in the 3-position, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.
    Type: Application
    Filed: June 18, 2020
    Publication date: December 10, 2020
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Michael Hahn, Thomas Lampe, Johannes-Peter Stasch, Karl-Heinz Schlemmer, Frank Wunder, Volkhart Min-Jian Li, Eva Maria Becker-Pelster, Friederike Stoll, Andreas Knorr, Elisabeth Woltering
  • Substituted 5-fluoro-1H-pyrazolopyridines and their use
    Patent number: 10736896
    Abstract: The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: August 11, 2020
    Assignee: ADVERIO PHARMA GMBH
    Inventors: Markus Follmann, Johannes-Peter Stasch, Gorden Redlich, Jens Ackerstaff, Nils Griebenow, Walter Kroh, Andreas Knorr, Eva-Maria Becker, Frank Wunder, Volkhart Min-Jian Li, Elke Hartmann, Joachim Mittendorf, Karl-Heinz Schlemmer, Rolf Jautelat, Donald Bierer
  • Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use
    Patent number: 10662185
    Abstract: The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides of the general formula (I) to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: May 26, 2020
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros Vakalopoulos, Markus Follman, Ingo Hartung, Philipp Buchgraber, Rolf Jautelat, Jorma Haßfeld, Niels Lindner, Alexey Gromov, Frank Wunder, Johannes-Peter Stasch, Gorden Redlich, Volkhart Min-Jian Li, Eva Maria Becker-Pelster, Andreas Knorr
  • AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE
    Publication number: 20190248783
    Abstract: The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: July 2, 2018
    Publication date: August 15, 2019
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros VAKALOPOULOS, Markus FOLLMAN, Ingo HARTUNG, Philipp BUCHGRABER, Rolf JAUTELAT, Jorma HAßFELD, Niels LINDNER, Alexey GROMOV, Frank WUNDER, Johannes-Peter STASCH, Gorden REDLICH, Volkhart Min-Jian LI, Eva Maria BECKER-PELSTER, Andreas KNORR
  • BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE
    Publication number: 20190185415
    Abstract: The present application relates to novel 3-phenylpropionic acid derivatives which carry a branched or cyclic alkyl substituent in the 3-position, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.
    Type: Application
    Filed: December 21, 2018
    Publication date: June 20, 2019
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Michael HAHN, Thomas LAMPE, Johannes-Peter STASCH, Karl-Heinz SCHLEMMER, Frank WUNDER, Volkhart Min-Jian LI, Eva-Maria BECKER-PELSTER, Friederike STOLL, Andreas KNORR, Elisabeth WOLTERING
  • Heteroaryl-substituted imidazo[1,2-A]pyridines and their use
    Patent number: 10292970
    Abstract: The present application relates to novel heteroaryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: May 21, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros Vakalopoulos, Damian Brockschnieder, Frank Wunder, Johannes-Peter Stasch, Tobias Marquardt, Lisa Dietz, Volkhart Min-Jian Li
  • STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF
    Publication number: 20190125709
    Abstract: The present invention relates to stimulators and activators of soluble guanylate cyclase in combination with an inhibitor of neutral endopeptidase and/or angiotensin AII antagonists and the use thereof for the treatment and/or prophylaxis of cardiovascular disorders, for example heart failure with preserved ejection fraction or heart failure with reduced ejection fraction, renal disorders, for example chronic kidney failure, urological disorders, lung disorders, disorders of the central nervous system, for regulation of cerebral perfusion, for example in the event of vascular cerebral states of dementia, for the treatment and/or prophylaxis of fibrotic disorders and other disease symptoms (e.g. end organ damage affecting the brain, kidney or heart).
    Type: Application
    Filed: July 15, 2016
    Publication date: May 2, 2019
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Tobias MARQUARDT, Markus FOLLMANN, Johannes-Peter STASCH
  • SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis
    Patent number: 10265314
    Abstract: The present invention relates to soluble guanylate cyclase (sGC) and to phosphodiesterases (PDEs) and the pharmacology of sGC stimulators, sGC activators and PDE inhibitors (PDE5i) in combination with a) treatments, leading to increased cGMP mobilization, and/or b) tretaments correcting and/or potentiatiating CFTR function, and/or c) treatments currently used as standard of care in Cystic Fibrosis, and/or d) antinflammatory treatments for the preparation of medicaments for the treatment of Cystic Fibrosis (CF) with improved efficacy over methods of treatments already known.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: April 23, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Peter Sandner, Johannes-Peter Stasch, Michael Hahn, Markus Follmann
  • Branched 3-phenylpropionic acid derivatives and their use
    Patent number: 10259776
    Abstract: The present application relates to novel 3-phenylpropionic acid derivatives which carry a branched or cyclic alkyl substituent in the 3-position, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: April 16, 2019
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Michael Hahn, Thomas Lampe, Johannes-Peter Stasch, Karl-Heinz Schlemmer, Frank Wunder, Volkhart Min-Jian Li, Eva-Maria Becker-Pelster, Friederike Stoll, Andreas Knorr, Elisabeth Woltering
  • Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and use thereof
    Patent number: 10214526
    Abstract: The present application relates to novel substituted pyrazolo[1,5-a]pyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: February 26, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Alexandros Vakalopoulos, Damian Brockschnieder, Frank Wunder, Johannes-Peter Stasch, Tobias Marquardt, Lisa Dietz, Min Jian Volkhart Li
  • Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
    Patent number: 10189856
    Abstract: The use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and treatment of fibrotic diseases, such as systemic sclerosis, scleroderma, and the concomitant fibrosis of internal organs.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: January 29, 2019
    Assignee: Adverio Pharma GMBH
    Inventors: Claudia Hirth-Dietrich, Peter Sandner, Johannes-Peter Stasch, Andreas Knorr, Georges Von Degenfeld, Michael Hahn, Markus Follmann
  • Substituted pyrazolo[1,5-A]pyridines and their use
    Patent number: 10174021
    Abstract: The present application relates to novel substituted pyrazolo[1,5-a]pyridines of the formula (I-A) to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: January 8, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros Vakalopoulos, Damian Brockschnieder, Frank Wunder, Johannes-Peter Stasch, Tobias Marquardt, Lisa Dietz, Volkhart Min-Jian Li
  • N-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6- dimethylimidazo[1,2-a]pyrazin-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (SGC) for the treatment of cardiovascular diseases
    Patent number: 10150773
    Abstract: The present application relates to novel substituted imidazo[1,2-a]pyrazine carboxamides of general formula (I) to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: December 11, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Alexandros Vakalopoulos, Damian Brockschnieder, Frank Wunder, Johannes-Peter Stasch, Tobias Marquardt, Lisa Dietz, Min Jian Volkhart Li